WO2017150763A1 - Modèle animal exprimant cd3 humain et son utilisation - Google Patents

Modèle animal exprimant cd3 humain et son utilisation Download PDF

Info

Publication number
WO2017150763A1
WO2017150763A1 PCT/KR2016/003358 KR2016003358W WO2017150763A1 WO 2017150763 A1 WO2017150763 A1 WO 2017150763A1 KR 2016003358 W KR2016003358 W KR 2016003358W WO 2017150763 A1 WO2017150763 A1 WO 2017150763A1
Authority
WO
WIPO (PCT)
Prior art keywords
human
animal model
mouse
gene
peptide
Prior art date
Application number
PCT/KR2016/003358
Other languages
English (en)
Korean (ko)
Inventor
김선택
류기혁
박상래
곽성성
정현호
양기혁
Original Assignee
(주)메디톡스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)메디톡스 filed Critical (주)메디톡스
Publication of WO2017150763A1 publication Critical patent/WO2017150763A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Definitions

  • the present invention relates to a human CD3 expression animal model and its use, and specifically, to an animal model into which a gene encoding human CD3 is introduced, a method for preparing the animal model, and a therapeutic agent for T cell mediated disease using the animal model. It relates to a method of screening.
  • the human adaptive immune system is a very sophisticated system that can specifically remove not only various infectious diseases but also cancer cells.
  • T cells in the case of T cells, it plays a role in determining cellular adaptive immunity and recognizes and removes cells when exposed to non-self or abnormal antigens.
  • T cells a monoclonal T cell receptor complex (TCR complex) is expressed on the cell membrane to generate a major histocompatibility complex (peptide, pMHC) of an antigen presenting cell (APC).
  • pMHC major histocompatibility complex
  • APC antigen presenting cell
  • T cells it expresses 20,000-40,000 TCR molecules per cell and specifically recognizes several antigens (determined by peptide sequence) of 100,000 pMHC molecules of APC to initiate signal transduction.
  • the TCR molecule must serve as a highly sensitive sensor that must recognize and transmit signals with very sophisticated and subtle antigenic changes.
  • Such cellular adaptive immunity must be operated with great sophistication to effectively remove infectious diseases and cancer cells of the human body. If the antigen specific adaptive immune system does not work, it poses serious problems with infectious disease response and cancer cell clearance. On the other hand, when cellular adaptive immunity is activated by recognizing human self antigens, autoimmune diseases that destroy self cells and tissues are induced.
  • the ⁇ TCR complex consists of an ⁇ heterodimer that specifically recognizes an antigen and CD3 molecules (CD3 ⁇ , CD3 ⁇ , CD3 ⁇ ) for signaling.
  • ⁇ heterodimer has a structure similar to that of an antibody Fab, and CD3 ⁇ , ⁇ , and ⁇ each have an Ig domain in an extracellular configuration.
  • Specific antigen recognition of the [alpha] [beta] heterodimer is mediated by the CD3 molecule to signal the cell.
  • This signaling is known to be T-cell activation by intracellular tyrosine kinase (LCK, ZAP70, LAT, PLC ⁇ ) phosphorylation, cytoplasmic Ca ++ concentration changes and intracellular transcriptional system changes.
  • each domain structure was determined by NMR and X-ray structure determination, and structural information on quaternary structure binding on T cell membranes was revealed one by one.
  • the specific binding of the extracellular domain is very weak, while the electrical binding of charged amino acids in the cell membrane is important, suggesting that it can be amplified by the environment within the cell membrane.
  • the important role of human CD3 ⁇ for T cell signaling is known, and the major crystal structures of the complexes bound to OKT3 being used as therapeutic antibodies have recently been described (Kjer-Nielsen, PNAS 101, (2004), 7675). -7680).
  • CD3 molecules Signal transduction mechanisms of TCR were found to be mediated by CD3 molecules. Based on this, various CD3 antibodies have been developed for T cell signal transduction research and T cell activation regulation.
  • CD3 monoclonal antibodies are widely used clinically in immunosuppressive therapy.
  • OKT3, a CD3-specific mAb was the first mAb licensed for use in humans and was used as an immunosuppressive agent in clinical transplantation.
  • CD3 monoclonal antibodies are generally due to the species specificity of the CD3 molecule, which is the target molecule.
  • OKT3 the most widely used CD3 antibody, reacts with chimpanzee CD3 but not with other primates, macaques monkeys or CD3 in dogs.
  • Most human CD3 antibodies bind only to human CD3 molecules, while CD3 molecules from mice, rats, rabbits, rhesus monkeys, cynomolgus monkeys, or baboon monkeys for preclinical experiments Do not combine.
  • Drug antibody candidates can be tested for safety in animals in two general ways: First, the antibody candidate may utilize a related animal species capable of recognizing orthologous antigens or an antibody candidate surrogate capable of binding to the parallel homologous antigens present in the animal.
  • a disadvantage in the development of most therapeutic candidate monoclonal antibodies is that candidate monoclonal antibodies should only be tested in the relevant animal species in high-quality primates, particularly chimpanzees. Chimpanzees are an endangered species and therefore the use of these animals for safety testing is very limited.
  • TCR signaling can be altered not by CD3 antibody binding capacity or number of binding antibodies, but by the mode of binding of antibodies that bind CD3 (a recognized epitope). These results show that the use of an antibody candidate surrogate that can bind to parallel homologous antigens may differ from the equivalent signaling results.
  • Transgenic animal models incorporating only the human CD3 ⁇ coding gene have been reported to have serious problems with T cell differentiation and production (PNAS 1994 91 (20) 9402-9406). For this reason, transgenic animals which only introduce the human CD3 ⁇ coding gene are highly likely to cause problems throughout the immune system, and therefore, they are very limited to be used as experimental animals for immune diseases.
  • the inventors of the present application have prepared a genetically modified animal incorporating a human CD3 coding gene, presenting a method for evaluating efficacy in a disease model prepared according to the present invention, In this case, the present invention was completed by confirming that it can be used as a disease model without changing the rodent immune system.
  • An object of the present invention is to provide a transgenic animal model incorporating human CD3.
  • An object of the present invention is to provide a method for producing the animal model.
  • An object of the present invention is to provide a method for screening a therapeutic agent for T cell mediated diseases using the animal model.
  • the present invention provides a human CD3 expressing animal model into which a gene encoding human CD3 is introduced.
  • the present invention also provides a method for producing a human CD3 expressing animal model comprising introducing the gene encoding the human CD3 into an animal.
  • the present invention also comprises the steps of treating or administering a candidate to the human CD3 expression animal model; And it provides a method for screening a T-cell mediated disease therapeutic agent comprising the step of selecting a candidate for reducing the human CD3 expression compared to the control agent.
  • Figure 1 shows the results of phenotypic analysis of thymus and spleen cells derived from huCD3 ⁇ -TG mouse.
  • Figures 2a to 2d shows the results of confirming whether the response to the ⁇ -human CD3 antibody and / or ⁇ -mouse CD3 antibody of huCD3 ⁇ -TG mouse.
  • FIG 3 shows a schematic diagram of the back skin animal model experiment design (A) and ear skin animal model experiment design (B).
  • IMQ Imiquimod
  • FIG 4 shows the results of T lymphocyte flow cytometry before and after administration of anti-human CD3 antibody (OKT3) to transgenic mice at 6 hours, 24 hours and 48 hours.
  • Figure 5 shows a photograph of the skin symptoms by anti-CD3 antibody (OKT3) treatment and control (Isotype control) in imiquimod induced psoriasis skin disease.
  • Figure 6 shows the results of PASI by anti-CD3 antibody (OKT3) treatment and control (Isotype control) in imiquimod induced psoriasis skin disease. a-b Other letters on the test day indicate a significant difference.
  • Statistical analysis was performed on the test groups (PBS, OKT3, Isotype control) except for the VAS group. Tukey's post hoc test.
  • VAS Vaseline
  • PBS Phosphate buffered saline.
  • VAS Vaseline
  • PBS Phosphate buffered saline.
  • FIG. 10 shows the results of T lymphocyte analysis in blood on day 12 of the ear skin psoriasis induction model by imiquimod. a-b Other characters mean significant differences. Tukey's post hoc test.
  • Figure 11 shows the results of mouse and human CD3 expressing T lymphocytes in blood on day 12 of the ear skin psoriasis induction model.
  • Figure 12 shows the results of inflammatory cell analysis in the skin of psoriasis induced ear. a- c Other characters mean significant differences. Tukey's post hoc test.
  • Figure 13 shows the histopathological findings and evaluation results of mouse ear skin. a- c Other characters mean significant differences. Tukey's post hoc test.
  • the present invention relates to a human CD3 expressing animal model into which a gene encoding human CD3 is introduced.
  • CD3 molecules are the major molecules that mediate the signal transduction of T cell antigen receptor complexes and are the main targets for immunotherapy treatment. CD3 molecules have very high barriers to animal model utilization and validation using human CD3 antibodies due to their interspecificity. The present invention can be used in evaluating the efficacy of the human CD3 molecule as a disease model to overcome the problems of introducing animal models of other species.
  • the gene encoding human CD3 may be transformed with a cloned vector.
  • vector refers to a nucleic acid molecule delivered into a cell and may include an "expression vector” for replicating DNA and expressing in a host cell.
  • the expression vector is a recombinant DNA molecule comprising a coding sequence of interest and a suitable nucleic acid sequence necessary for expressing a coding sequence operably linked in a specific host organism, and if necessary, a promoter, a transcriptional regulatory sequence (e.g., an enhancer sequence). ), Transcription termination factors, and the like.
  • Promoter means a non-readed nucleic acid sequence upstream of a coding region that contains a binding site for polymerase and has a transcription initiation activity to mRNA of a promoter lower gene.
  • the promoter is operably linked to induce the expression of a gene of interest, a foreign gene, and "operably linked" means that the binding between nucleic acid sequences is functionally related.
  • the case where any nucleic acid sequence is operably linked is when any nucleic acid sequence is positioned to be functionally related to another nucleic acid sequence.
  • Operative linkage with recombinant vectors can be prepared using genetic recombination techniques well known in the art, and site-specific DNA cleavage and ligation can employ enzymes commonly known in the art.
  • the target gene is a human CD3 coding gene
  • CD3 is a molecule that transmits a signal from an ⁇ TCR heterodimer that specifically recognizes an antigen in a TCR complex structure, and includes an Ig domain in an extracellular configuration, and ⁇ hetero Signaling takes place into cells via CD3 after recognition of the specific antigen of the dimer.
  • the human CD3 may be CD3 ⁇
  • the gene encoding human CD3 may be a structure in which the CD3 ⁇ coding gene of SEQ ID NO: 1 and the CD3 ⁇ coding gene of SEQ ID NO: 2 are linked by a self-cleaving peptide coding gene.
  • the autologous cleavage peptide coding gene is located between the CD3 ⁇ coding gene and the CD3 ⁇ coding gene, autologous cleavage occurs during translation and divides it into two CD3 ⁇ and CD3 ⁇ .
  • the self-cleaving peptide may be, for example, a 2A peptide.
  • the 2A peptides for example, P2A peptides encoded by the sequence of SEQ ID NO: 3 (SEQ ID NO: 5 is an amino acid sequence) can be used. P2A peptides have superior cleavage efficiency compared to 2A peptides with other sequences.
  • CD3 ⁇ and CD3 ⁇ each CD3 gene is linked to the 2A peptide, which is a self-cleaving peptide, thereby simultaneously transcribing from transcription to protein translation to minimize the interference effect on CD3 in transgenic animal models.
  • the transcription terminator may include any transcription terminator known in the art, for example, may be poly A linked.
  • the vector may be a linear DNA, a plasmid DNA or a recombinant viral vector, wherein the recombinant viral vector is a retrovirus, adenovirus, herpes simplex virus and lentivirus. ), But is not limited thereto.
  • Transformation may mean changing genetic properties to have new genotypes by recombinant DNA techniques and germ cell engineering methods, rather than by traditional crosses. Transformation may include somatic transformation and germ cell transformation. Somatic transformation may mean that the newly acquired genotype appears in the current generation of animals but is not passed on to the next generation. On the other hand, germ cell transformation refers to a case where a new gene is transferred directly to germ cells or a transformed cell is transferred to germ cells so that a new genotype is transmitted not only to the current generation but also to the next generation. In general, the production of a truly transgenic animal is through germ cell transformation.
  • transgenic animals can be carried out using a variety of known methods, such as microinjection, electroporation, particle bombardment, methods using viral vectors, methods using embryonic stem cells, nuclear transfer. Methods, direct muscle injection, insulators, transposons, or methods using sperm.
  • a transgenic animal model was prepared by linearly injecting a vector including a gene to be introduced into a fertilized egg (Example 1). Genetic modification may include the case where the desired gene is introduced randomly and when introduced at a specific site.
  • the animal model may be, for example, a rodent including a mouse and the like.
  • a human CD3 expressing transgenic mouse transformed with a vector containing a gene encoding human CD3 was prepared and analyzed.
  • human CD3 is normally expressed in T lymphocytes and works functionally.
  • the present invention relates to a method for producing a human CD3 expressing animal model comprising introducing a gene encoding the human CD3 into an animal.
  • Human CD3 expression animal model production method also includes a process for introducing a human CD3 coding gene, for example, CD3 ⁇ coding gene and CD3 ⁇ coding gene by linking with a self-cleaving peptide coding gene and cloning the vector into the animal, the configuration is As it overlaps with the components included in the transgenic animal model mentioned, the description applies equally.
  • the present invention comprises the steps of treating or administering a candidate to the human CD3 expression animal model; And it relates to a method for screening a T-cell mediated disease therapeutic agent comprising the step of selecting a candidate for reducing the human CD3 expression compared to the control agent.
  • CD3 molecules have very high barriers to animal model utilization and validation using human CD3 antibodies due to their interspecificity.
  • the present invention overcomes the problem of introducing human CD3 molecules into other animal models, and can utilize a human CD3 expressing animal model to evaluate the efficacy of a drug for treating T cell mediated diseases.
  • the candidates are suspected of having the potential to inhibit CD3 expression or activity according to conventional selection or randomly selected individual test subjects, eg, compounds, natural products, antisense nucleotides, short interfering RNA ), Short hairpin RNAs, aptamers or antibodies, but are not limited thereto.
  • the measurement of CD3 expression amount change can be carried out through various methods known in the art.
  • the CD3 expression level change can be measured, for example, changes in gene expression levels, for example reverse transcriptase polymerase reaction, competitive reverse transcriptase polymerase reaction, real time reverse transcriptase polymerase reaction, RNase protection assay, Northern blotting Or via a DNA chip.
  • the CD3 expression level change can be measured, for example, protein expression levels, for example Western blot, ELISA, radioimmunoassay, radioimmunoproliferation method, oukteroni immunodiffusion method, rocket immunoelectrophoresis, tissue immunity Staining, immunoprecipitation assays, complement fixation assays, FACS or protein chips.
  • T cell mediated disease refers to a condition caused by the proliferation or activity of T cells, and may include, for example, cancer or autoimmune diseases.
  • a construct was constructed in which a full-length CD3 ⁇ DNA (SEQ ID NO: 1) and a CD3 ⁇ DNA (SEQ ID NO: 2) were linked with a 2A peptide to a pCAGGS vector used for animal cell expression.
  • the 2A peptide is encoded by SEQ ID NO: 3, which is present in the virus and located between the large proteins causes self-cleavage during translation to divide the proteins. This allows the two proteins to be expressed in a single plasmid, with the advantage that the amounts expressed are about the same.
  • the 2A peptide used in this experiment is the P2A peptide of SEQ ID NO: 3 and has a higher cleavage efficiency than the 2A peptide of other sequences.
  • a separate spacer (SEQ ID NO: 4) was connected to the 5 'direction of the P2A peptide.
  • the amino acid sequence of the construct including the CD3, P2A peptide and the spacer included in the vector used for constructing the transgenic mouse is as described in SEQ ID NO: 6, and the gene sequence encoding it is as described in SEQ ID NO: 7.
  • the prepared plasmid was cut and linearized by restriction enzymes, and microinjected into fertilized eggs of mice. The procedure was followed according to standard procedures, and individuals transformed with human CD3 ⁇ were selected by genomic PCR.
  • Example 1 Analysis of the transgenic mouse model prepared in Example 1 was performed as follows. Wild type mice (B6) and transgenic mice (human CD3 ⁇ ) of 4-5 weeks old were used. Cells were isolated by homogenizing tissue (thymus, spleen). After centrifugation at 400 g for 5 minutes, the supernatant was removed, and 500 ⁇ l of RBC lysis buffer (sigma, # R7757) was added thereto, followed by suspension for 2 minutes to remove red blood cells. 10 ml of medium (RPMI1640, 10% FBS) was added and diluted, and the supernatant was removed by centrifugation at 400 g for 5 minutes. 5 x 105 cells were used per experiment.
  • Wild type mice (B6) and transgenic mice (human CD3 ⁇ ) of 4-5 weeks old were used. Cells were isolated by homogenizing tissue (thymus, spleen). After centrifugation at 400 g for 5 minutes, the supernatant was removed, followed by suspension for 2 minutes to remove red blood cells. 10 m
  • mice Fc blocker 0.5 ug of mouse Fc blocker (BD, # 553141) was added and incubated at 4 ° C. for 5 minutes.
  • Anti-mouse CD4-V450 (RM4-5, BD, # 560468), anti-mouse CD8-V500 (53-6.7, BD, # 560776), anti-mouse CD3-A647 (17A2, BD, # 557869), anti Dilute mouse CD3-A488 (UCHT1, BD, # 557694) antibodies with buffer (PBS, 2% FBS, 0.05% sodium azide) in a ratio of 1:50 to make a master mix and add 20ul per experiment The exposure to light was blocked and stained for 20 minutes at 4 ° C. After centrifugation at 400g for 5 minutes, the supernatant was removed and washed twice with 100ul buffer. Finally, the cells were suspended in 200ul buffer and measured by FACSVerse (BD).
  • FIG. 1 The results are shown in FIG. 1, and according to FIG. 1, it was confirmed that human CD3 was specifically expressed in transgenic mice (TG). Thymic analysis revealed that T cell differentiation and development was the same as wild type mice (WT).
  • PBMCs Peripheral blood mononuclear cells
  • the suspension was resuspended with 1 ml of medium.
  • the cells were filtered with a cell strainer (352352) to complete PBMC separation.
  • Cells were stimulated by incubating for 1 hour in 1 ml each of wells and uncoated wells coated with an anti-CD3 antibody at a concentration of 1 ⁇ 10 6 cells (splenocytes, human PBMC) / ml.
  • the cells were collected by 150ul and centrifuged at 400g for 5 minutes to remove supernatant and washed with buffer (PBS, 2% FBS, 0.05% sodium azide).
  • buffer PBS, 2% FBS, 0.05% sodium azide
  • Anti-mouse CD4-V450 (RM4-5, BD, # 560468), anti-mouse CD8-V500 (53-6.7, BD, # 560776), anti-mouse CD3-A647 (17A2, BD, # 557869), anti Human CD3-A488 (UCHT1, BD, # 557694) antibody was diluted 1:50 with buffer and added to 20 ⁇ l of WT, TG splenocytes samples to block exposure to light at 4 ° C. for 20 minutes and stained.
  • Anti-mouse CD4-V450 (RM4-5, BD, # 560468), anti-mouse CD8-V500 (53-6.7, BD, # 560776), anti-mouse CD69-A488 (H1.2F3, biolegend, # 104516) , Anti-mouse CD25-PE (3C7, BD, # 553075) antibody was diluted 1:50 with buffer and added in 20 ul of WT, TG splenocyte samples to block exposure to light and stain for 20 minutes at 4 ° C. It was.
  • Anti-human CD4-V450 (RPA-T4, BD, # 560345), anti-human CD8-V500 (RPA-T8, BD, # 560774), anti-human CD3-A488 (UCHT1, BD, # 557694), anti Human CD69-APC-H7 (FN50, BD, # 560737) antibody was diluted 1:50 with buffer and added to 20 ⁇ L of human PBMC samples to block exposure to light at 4 ° C. for 20 minutes and stained.
  • Anti-human CD4-V450 (RPA-T4, BD, # 560345), anti-human CD8-V500 (RPA-T8, BD, # 560774), anti-human CD3-A488 (UCHT1, BD, # 557694), anti -Dilute human CD25-PerCP-Cy5.5 (M-A251, BD, # 560503) antibody with buffer at a ratio of 1:50 and add 20ul to human PBMC samples to block light exposure at 4 ° C for 20 minutes. Stained. After centrifugation at 400g for 5 minutes, the supernatant was removed and washed twice with 100ul buffer. Finally, the cells were suspended in 100ul buffer and measured with FACSVerse (BD).
  • BD FACSVerse
  • T cells derived from transgenic mice are activated by UCHT1, a human CD3 specific antibody.
  • mice Female or male transgenic mice (huCD3 ⁇ +/ ⁇ ) and normal mice of 8-9 weeks of age were supplied from macrogen and used in the experiment. Two normal mice and seven transgenic mice were used in experiments to confirm expression of human CD3 introduced into transgenic mice and responses to anti-human CD3 antibodies (OKT3). Orbital vein bleeding was performed 6 hours, 24 hours and 48 days after administration of the antibody, and the fluorescently labeled antibody was used to measure the expression of human CD3 and the number of T lymphocytes by flow cytometry.
  • mice Twenty-one female transgenic mice were used for the dorsal skin model, and sixteen male transgenic mice were used for the ear skin model.
  • the mouse abdominal cavity was anesthetized by injection anesthesia solution (ketamine + xylazine mixture), and the back hairs were removed using a hair removal machine and the remaining hairs were completely removed using a hair removal cream (VEET).
  • the back skin model is applied with 62.5 mg aldara cream (5% imiquimod Imiquimod) for 4 days every day using spatula to induce psoriasis on the back (van der Fits et al.
  • Psoriasis Area and Severity Index (PASI) assessment was applied (van der Fits et al. 2009). Erythema, scaling, and skin thickening were evaluated. Each item was evaluated by 0-4 points (0: normal, 1: weak, 2: moderate, 3: severe, 4: very severe). Back and skin thicknesses were measured using a vernier caliper, and psoriasis lesions on the back skin were photographed using a digital camera and stereomicroscope (SMZ18, Nikon). Ear skin model measured the thickness of both ears using a vernier caliper and used the average of both ears. Psoriasis lesions were evaluated by two evaluators, and the score of each assessment item was added to evaluate the extent of psoriasis with a total score of 0-12.
  • Psoriasis lesions were evaluated by two evaluators, and the score of each assessment item was added to evaluate the extent of psoriasis with a total score of 0-12.
  • ear skin model was orbital vein collected from 3 to 4 mice per test group on day 12.
  • the left ear was removed and 400 U / mL collagenase IV (17104-019, Gibco) and 200 U / mL hyaluronidase (H3506, Sigma) were placed in PBS for flow cytometry. Incubated for 1 hour at 36 °C, 5% CO 2 conditions to separate into single cells.
  • the blood samples and single cells of the ear skin were reacted with the antibody diluted at a ratio of 1: 100 at room temperature for 30 minutes, centrifuged at 400xg for 5 minutes, and washed twice with 100 ⁇ L of buffer.
  • Antibodies used in flow cytometry are as follows. Anti-mouse CD3-A647 (17A2, BD, # 557869), anti-human CD3-PE (UCHT1, BD, 555333), anti-mouse CD4-V450 (RM4-5, BD, # 560468), anti-mouse CD8a -V500 (53-6.7, BD, # 560776), anti-mouse CD69-A488 (H1.2F3, Biolegend, # 104516), anti-mouse CD11b-A647 (M1 / 70, Biolegend, # 101218), anti-mouse Gr-1-A488 (RB6-8C5, Biolegend, # 108417), anti-mouse F4 / 80-PE (BM8, Biolegend, # 123110), anti-CD16 / CD32 (2.4G2, BD, # 553142).
  • Psoriasis-induced back or ear skin tissues were fixed in 10% neutral formalin at room temperature for 3 to 4 days, followed by paraffin embedding (Microm STP-120, Thermo scientific), and then cut into 5 ⁇ m size (Microm HM 340E, Thermo scientific). ) To make two or more slides per sample. The dissected tissue was subjected to H & E staining and histopathological evaluation and imaging under a microscope (FSX100, Olympus). 0-4 points (0: normal, 1: weak) for epidermal edema / hyperplasia and immune cell influx in at least 5 zones randomly selected by two evaluators for all tissue samples. , 2: moderate, 3: severe, 4: very severe).
  • Induction of psoriasis by imiquimod significantly reduced the number of mouse CD4 + and CD8 + T lymphocytes in the blood on the 3rd day compared to the petrolatum group, and in particular, the OKT3 administration group significantly reduced the number of T lymphocytes than the PBS administration group (FIG. 7). ).
  • Imiquimod showed psoriasis abnormal keratinization, epidermal thickening, hyperplasia of keratinocytes and infiltration of inflammatory cells.
  • the thickness of the epidermis was reduced compared to the group administered with PBS or control (Isotype control), and the infiltration and abnormal keratinization of inflammatory cells were also reduced (FIG. 8).
  • the OKT3 group scored significantly lower than PBS and Isotype control.
  • Psoriasis skin thickening occurred by the application of imiquimod to both ears, and skin thickness was significantly reduced by three OKT3 administrations from day 7 (FIG. 9).
  • OKT3 administration showed a decrease in epidermal thickness and inflammatory cell infiltration, and when scored, the OKT3 administration group was significantly lower than the control (Isotype control) (FIG. 13).
  • Psoriasis was induced in the back and ear skin using imiquimod using human CD3 expressing transgenic mice and then tested with anti-human CD3 antibody (OKT3).
  • Mouse T lymphocyte activation and depletion reduced the number of T lymphocytes and inflammatory cells in blood and psoriasis skin tissue.
  • administration of anti-human CD3 antibody significantly reduced psoriasis skin symptoms and histopathology.
  • anti-human CD3 antibody may have a therapeutic effect in psoriasis.
  • T lymphocytes play an important role in psoriasis induction process, and it can be confirmed that human CD3 of the manufactured transgenic mouse functionally works in mouse T lymphocytes.
  • Human CD3 expressing transgenic mice are likely to be used in various experiments, such as antibody screening of human CD3 targets and confirmation of antibody therapeutic efficacy in autoimmune diseases such as psoriasis.
  • the transgenic human CD3 expressing animal model into which the gene encoding human CD3 according to the present invention is introduced can be used as a disease model without changing the immune system of the animal model. Through this, a transgenic animal model expressing human CD3 can be applied for drug evaluation or screening for T cell mediated disease therapeutics.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Food Science & Technology (AREA)

Abstract

La présente invention se rapporte à un modèle animal exprimant CD3 humain et une utilisation de celui-ci, et plus particulièrement à : un modèle animal dans lequel un gène codant pour CD3 humain a été introduit; elle se rapporte également à un procédé de production de ce modèle animal, ainsi qu'à un procédé de criblage d'un agent de thérapie de maladies à médiation lymphocytaire T, à l'aide du modèle animal.
PCT/KR2016/003358 2016-02-29 2016-03-31 Modèle animal exprimant cd3 humain et son utilisation WO2017150763A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160024576 2016-02-29
KR10-2016-0024576 2016-02-29

Publications (1)

Publication Number Publication Date
WO2017150763A1 true WO2017150763A1 (fr) 2017-09-08

Family

ID=59744177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003358 WO2017150763A1 (fr) 2016-02-29 2016-03-31 Modèle animal exprimant cd3 humain et son utilisation

Country Status (1)

Country Link
WO (1) WO2017150763A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109913493A (zh) * 2017-12-12 2019-06-21 百奥赛图江苏基因生物技术有限公司 人源化cd3基因改造动物模型的制备方法及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530179A (en) * 1993-03-03 1996-06-25 Beth Israel Hospital Association Transgenic immunodeficient animal models
US20070209083A1 (en) * 2001-07-13 2007-09-06 Genoway Cell and transgenic animal modelling human antigenic presentation and their uses
EP2660250A1 (fr) * 2012-05-02 2013-11-06 Deutsches Rheuma-Forschungszentrum Berlin Modèle de souris transgénique TCR destiné à une maladie immunitaire
CN105164153A (zh) * 2013-02-20 2015-12-16 瑞泽恩制药公司 人源化的t细胞共受体的小鼠

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530179A (en) * 1993-03-03 1996-06-25 Beth Israel Hospital Association Transgenic immunodeficient animal models
US20070209083A1 (en) * 2001-07-13 2007-09-06 Genoway Cell and transgenic animal modelling human antigenic presentation and their uses
EP2660250A1 (fr) * 2012-05-02 2013-11-06 Deutsches Rheuma-Forschungszentrum Berlin Modèle de souris transgénique TCR destiné à une maladie immunitaire
CN105164153A (zh) * 2013-02-20 2015-12-16 瑞泽恩制药公司 人源化的t细胞共受体的小鼠

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUHN, CHANTAL ET AL.: "Human CD 3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance", SCIENCE TRANSLATIONAL MEDICINE, vol. 3, no. 68, 2 February 2011 (2011-02-02), XP055249939 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109913493A (zh) * 2017-12-12 2019-06-21 百奥赛图江苏基因生物技术有限公司 人源化cd3基因改造动物模型的制备方法及应用
US10945420B2 (en) 2017-12-12 2021-03-16 BiocytogenPharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric CD3e

Similar Documents

Publication Publication Date Title
Jenkins et al. Effects of cyclosporine A on T cell development and clonal deletion
CN106068276B (zh) 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
Fowlkes et al. A novel population of T-cell receptor αβ-bearing thymocytes which predominantly expresses a single V β gene family
Martin et al. Immunological aspects of demyelinating diseases
Malarkannan et al. Differences that matter: major cytotoxic T cell–stimulating minor histocompatibility antigens
O’Brien et al. γδ T‐cell receptors: functional correlations
Teh et al. Participation of CD4 coreceptor molecules in T-cell repertoire selection
Li et al. Emerging roles for the FCRL family members in lymphocyte biology and disease
HU228477B1 (en) Pd-1, a receptor for b7-4, and uses therefor
JPH09500788A (ja) Ｂ７−２：ｃｔｌａ４／ｃｄ２８カウンターレセプター
Kyewski Thymic nurse cells: possible sites of T-cell selection
JPH04506752A (ja) チロトロピンレセプター活性を有するポリペプチド、このレセプターとポリペプチドとをコードする核酸、そしてこのようなペプチドの利用
Morimoto et al. Aire suppresses CTLA-4 expression from the thymic stroma to control autoimmunity
Huang et al. Distinctive selection mechanisms govern the T cell receptor repertoire of peripheral CD4-CD8-alpha/beta T cells.
JP2007523640A (ja) 免疫応答を誘導または調節する方法
Seddon et al. CD4+ CD8− thymocytes that express L‐selectin protect rats from diabetes upon adoptive transfer
Loo et al. The mammalian LINC complex component SUN1 regulates muscle regeneration by modulating drosha activity
WO2017150763A1 (fr) Modèle animal exprimant cd3 humain et son utilisation
CN113337514A (zh) Tcr表达构建体以及其制备方法和用途
Kondo et al. Cloning of cDNAs for new subtypes of murine low-affinity Fc receptor for IgE (FcεRII/CD23)
WO2023063804A1 (fr) Procédé pour améliorer les lymphocytes t cd8+ anti-tumoraux en ciblant l'axe de signalisation pellino1-pkcθ
WO2018212503A1 (fr) Protéine cotl1 impliquée dans le maintien de l'homéostasie d'une cellule souche hématopoïétique, et utilisation associée
Abe et al. Genetic analysis of the Mls system. Formal Mls typing of the commonly used inbred strains
Lau et al. Characterisation of RT1-E2, a multigenic family of highly conserved rat non-classical MHC class I molecules initially identified in cells from immunoprivileged sites
Mellor et al. Expression and function of Qa-2 major histocompatibility complex class I molecules in transgenic mice

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16892776

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 16892776

Country of ref document: EP

Kind code of ref document: A1